e-learning
resources
Virtual 2020
Pre-Congress Content
Pathophysiology of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL)
A. Frost (Houston, United States of America), C. Zhao (South San Francisco, United States of America), H. Farber (Boston, United States of America), R. Benza (Pittsburgh, United States of America), M. Selej (South San Francisco, United States of America), G. Elliott (Murray, United States of America)
Source:
Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Session:
Pathophysiology of pulmonary hypertension
Session type:
E-poster session
Number:
3552
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Frost (Houston, United States of America), C. Zhao (South San Francisco, United States of America), H. Farber (Boston, United States of America), R. Benza (Pittsburgh, United States of America), M. Selej (South San Francisco, United States of America), G. Elliott (Murray, United States of America). Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL). 3552
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension
Year: 2019
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Age, risk and outcomes in idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018
Year: 2018
Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2006; 28: Suppl. 50, 425s
Year: 2006
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Risk stratification in pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – New trends in the management of pulmonary hypertension
Year: 2018
Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Survival in pulmonary hypertension in Spain: insights from the Spanish registry},
Source: Eur Respir J 2012; 40: 596-603
Year: 2012
An international survey of current pulmonary arterial hypertension (PAH) management
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Epidemiological and Clinical aspects of pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018
Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases
Year: 2016
Em
PH
asis-10 is associated with clinical outcome measures in pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Cambridge pulmonary hypertension outcomes review (CAMPHOR) utility assessment in pulmonary hypertension (PH) patients
Source: Annual Congress 2007 - Pulmonary hypertension in the clinic
Year: 2007
The study of risk in pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21:234-238
Year: 2012
The French registry of pulmonary arterial hypertension in children: characteristics at diagnosis
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept